复方丹参注射液治疗孕晚期羊水过少的疗效分析

所属专题：文献；

短篇论著

顾建珍¹^,^*(

)

全文 ( ) 下载PDF ( ) 导出引用

表1 3组治疗前、后脐动脉血流变化比较(±s)

Table 1 Comparison of umbilical artery flow changes among three groups before and after the treatment(±s)

表1 3组治疗前、后脐动脉血流变化比较(±s)

Table 1 Comparison of umbilical artery flow changes among three groups before and after the treatment(±s)

表2 3组治疗前、后血液流变学变化比较(±s)

Table 2 Comparison of hemorheological changes among three groups before and after the treatment(±s)

组别	BVL[(mPa·s)/10 L/s]		BVM[(mPa·s)/50(L/s)]		BVH[(mPa·s)/150 L/s]		HCT(%)
组别	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
实验Ⅰ组	6.68±0.56	5.60±0.68	4.43±0.31	3.61±0.29	3.63±0.29	3.14±0.18	35.36±2.10	34.08±1.66
实验Ⅱ组	6.43±0.48	5.38±0.70	4.35±0.26	3.57±0.18	3.56±0.17	3.12±0.18	34.68±1.93	33.92±1.68
对照组	5.22±0.36	5.31±0.43	3.50±0.22	3.54±0.17	2.99±0.19	3.04±0.22	32.40±1.80	33.20±2.06

表2 3组治疗前、后血液流变学变化比较(±s)

Table 2 Comparison of hemorheological changes among three groups before and after the treatment(±s)

组别	BVL[(mPa·s)/10 L/s]		BVM[(mPa·s)/50(L/s)]		BVH[(mPa·s)/150 L/s]		HCT(%)
组别	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
实验Ⅰ组	6.68±0.56	5.60±0.68	4.43±0.31	3.61±0.29	3.63±0.29	3.14±0.18	35.36±2.10	34.08±1.66
实验Ⅱ组	6.43±0.48	5.38±0.70	4.35±0.26	3.57±0.18	3.56±0.17	3.12±0.18	34.68±1.93	33.92±1.68
对照组	5.22±0.36	5.31±0.43	3.50±0.22	3.54±0.17	2.99±0.19	3.04±0.22	32.40±1.80	33.20±2.06

表3 3组妊娠结局比较[n(%)]

Table 3 Comparison of pregnant outcomes among three groups[n(%)]

组别	分娩时孕龄(±s，孕周)	剖宫产率	胎儿宫内窘迫发生率	新生儿窒息率	羊水粪染率
实验Ⅰ组	38.84±1.46	51(85.00)	20(33.33)	8(13.33)	19(31.67)
实验Ⅱ组	38.88±1.54	49(81.67)	19(31.67)	7(11.67)	17(28.33)
对照组	39.32±1.44	19(31.67)	7(11.67)	1 (1.67)	5 (8.33)

表3 3组妊娠结局比较[n(%)]

Table 3 Comparison of pregnant outcomes among three groups[n(%)]

组别	分娩时孕龄(±s，孕周)	剖宫产率	胎儿宫内窘迫发生率	新生儿窒息率	羊水粪染率
实验Ⅰ组	38.84±1.46	51(85.00)	20(33.33)	8(13.33)	19(31.67)
实验Ⅱ组	38.88±1.54	49(81.67)	19(31.67)	7(11.67)	17(28.33)
对照组	39.32±1.44	19(31.67)	7(11.67)	1 (1.67)	5 (8.33)

[1]	Chhabra S, Daragan R, Bawaskar R. Oligohydramnios: A potential marker for serious obstetric complications[J]. J Obstet Gynaecol, 2007, 27(7):680-683.
[2]	Dwinnell SJ, Coad S, Butler B, et al. In utero diagnosis and management of a fetus with homozygous α-Thalassemia in the second trimester: A case report and literature review[J]. J Pediatr Hematol Oncol, 2011, 33(8):358-360.
[3]	Taweevisit M, Thorner PS.Matern floor infarction associated with oligohydramnios and cystic renal dysplasia: Report of 2 cases[J].Pediatr Dev Pathol, 2010, 13(2):116-120.
[4]	Xu YH, Wen HW. Clinical analysis of 110 cases of oligohydramnios[J]. Matern Child Health Care China, 2007, 22(7):866-867.
[5]	Munn MB. Management of oligohydramnios in pregnancy[J].Obstet Gynecol Clin North Am, 2011, 38(2):387-395.
[6]	Liu GQ.Diagnosis and treatment advances in oligohydramnios[J].J Med Theory Pract, 2011, 24(14):1660-1661.
[7]	Ni J, Qiu YF, Sheng SQ, et al. Clinical effect of Fufang Danshen injection on treatment of late pregnancy hypamnion[J].Pract Clin J Integ Trad Chin Western Med, 2008, 8(4):42-43.
[8]	Li CF, Gou WL, Han Q.Investigation on treatment of fetal growth restriction by salvia injection combined with composite amino acid[J].Pract Clin J Integ Trad Chin Western Med, 2009, 29(1):68-71.

No related articles found!

阅读次数

全文

摘要